Rocket Pharmaceuticals, Inc. Construction Payable, Current
Rocket Pharmaceuticals, Inc. (RCKT) had Construction Payable, Current of $185.00 thousand as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Accounts Payable and Accrued Liabilities, Current
us-gaap:ConstructionPayableCurrent · last filed 2025-02-27
- 2024-12-31: Construction Payable, Current $185.00K.
- 2023-12-31: Construction Payable, Current $1.08M.
- 2023-09-30: Construction Payable, Current $1.67M.
- 2023-06-30: Construction Payable, Current $1.26M.
| Period end | Construction Payable, Current | Construction Payable, Current as first filed |
|---|---|---|
| 2024-12-31 | $185.00K 10-K · filed 2025-02-27 | |
| 2023-12-31 | $1.08M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $1.67M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.26M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $1.79M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $2.10M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $1.75M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $405.00K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.64M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $725.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.11M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $1.27M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $337.00K 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $1.76M 10-K · filed 2022-02-28 | $1.46M 10-K · filed 2021-03-01 |
| 2020-09-30 | $5.63M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $3.96M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $2.80M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $4.42M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $3.55M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $788.00K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $4.47M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |